Drug intelligence / Profile preview

ASAP-0017445

Development stage: Preclinical
Lead developer: Drugs for Neglected Diseases initiative
Modality: Small Molecules
Administration: Not Specified (likely Oral Based On Development Goals)

Overview

**ASAP-0017445** is a **broad-spectrum pan-coronavirus antiviral** that targets the main protease (3CL or Mpro) of coronaviruses, including SARS-CoV-2 and MERS-CoV. It was developed through an open-science and AI-driven approach by the COVID Moonshot initiative and the ASAP consortium. The compound is designed to be a direct-to-generic, globally accessible treatment for future coronavirus pandemics[1][2][3].

Other names: AS-0017445AS0017445AS 0017445

Targets

MERS-CoV 3CLpro (MERS-CoV main protease)Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on ASAP-0017445.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASAP-0017445.

Explore the full profile